Notably, mutations and methylation levels of YTHDC2 correlated with prognosis in specific cancers, with high diagnostic value demonstrated in cholangiocarcinoma, lung squamous cell carcinoma, thyroid carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma (SKCM), testicular germ cell tumors, and uterine carcinosarcoma, among others. The gene discussed is YTHDC2; the disease is thyroid gland carcinoma.